MPN is derived from hematopoietic stem cells (HSC) by driver mutation in JAK/STAT signaling genes and exhibits a propensity for transformation to secondary AML (sAML) by additional mutation gain (e.g. TP53, ASXL1, EZH2, SRSF2, IDH1). Here, TP53 is linked to myeloproliferative disorder.